secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000950170-24-053978
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus Q1 net loss narrows to $6.9M; raised $116M, cash runway through Q1 2027
------------------------------------------------------------------------------

- Net loss of $6.9M ($0.83/diluted share) vs $17.7M ($4.24) in Q1 2023, driven by lower operating expenses.
- Raised $116M in Q1 via public offering ($94.5M) and ATM ($21.1M); cash, equivalents & investments $120.1M.
- Phase 1 data for CRB-701 (next-gen Nectin-4 ADC) to be presented at ASCO 2024 on June 1, 2024.
- Appointed Dr. Dominic Smethurst as Chief Medical Officer; expects first CRB-913 patient dosed in Q1 2025.
- IND cleared for CRB-601 (anti-αvβ8 mAb); Phase 1 initiation expected summer 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024053978/0000950170-24-053978-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024053978/crbp-20240507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-053978

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer